Clinical Trial Update: Rifaximin on Visceral Hypersensitivity [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating rifaximin for visceral hypersensitivity and irritable bowel syndrome was terminated with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome
• Visceral Hypersensitivity

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Visceral Hypersensitivity, Irritable Bowel Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2022-09-13